长循环纳米制剂的构建策略及其相关研究进展

纳米载药系统承载着实现高效低毒治疗的良好期望，但其体内表现往往与体外研究结果差异显著，所载药物大多分布于富含巨噬细胞的肝、脾等脏器。这不仅限制了药效的提升，同时也给肝、脾等带来潜在的毒副作用。因此，延长体内循环时间，减少非靶部位聚集对于纳米制剂的临床转化具有重要意义。综述肝、脾等脏器对纳米制剂递药进程的影响以及近年来长循环系统的设计与构建策略研究进展，以期为相关研究提供参考。

Water-soluble superparamagnetic magnetite nanoparticles with biocompatible coating for enhanced magnetic resonance imaging

Although nano-drug delivery systems have been carrying the high expectations to realize enhanced therapeutic effect with reduced toxicity, their in vivo efficacy is often significantly different from the results of in vitro study. With a major fraction of the administered dose distributing in the organs with abundant accumulation of macrophages, e.g. liver and spleen, the improvement in drug efficacy is very limited and toxic and side effects may occur in these organs as well. Therefore, prolonged half-life of drugs and decreased unwanted accumulation in non-target sites are of great significance to the clinical translation of nano-formulations. This review mainly focused on the effects of related organs such as liver and spleen on the delivery of nanoparticles, and the recent progress in the strategies of designing and constructing long-circulating nano-carrier systems, so as to provide reference for related researches.